+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Paclitaxel Injection Market: By Indication - Global Industry Perspective Comprehensive Analysis and Forecast, 2019-2025

  • ID: 5144087
  • Report
  • November 2019
  • Region: Global
  • 130 pages
  • Zion Market Research
The report covers forecast and analysis for the Paclitaxel Injection market on a global and regional level. The study provides historic data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the Paclitaxel Injection market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Paclitaxel Injection market on a global level. In order to give the users of this report a comprehensive view on the Paclitaxel Injection market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein indication, End user, and regional segments are benchmarked based on their market size, growth rate and general attractiveness.

According to the report, global demand for Paclitaxel Injection Market was valued at approximately USD 2963.5 Million in 2018, and is expected to generate revenue of around USD 6628.6 Million by end of 2025, growing at a CAGR of around 12.19% between 2018 and 2025.

Paclitaxel injection is a gelatinous medication extracted after a chemical synthesis process from Pacific yew trees. It is a class of antineoplastic drug sub-segment that is used to treat breast, lung, ovary, abdomen, cervix, and other cancer. Infection with Paclitaxel targets tubulin, which in the human cell is a small globular protein. Under the guidance of an oncologist with expertise in chemotherapy, it should be administered. If a person has some allergic condition, the doctor does not prescribe it. Always check which patient does not suffer from high or low-pressure issue until prescribing this drug physician. Paclitaxel injection has several side effects such as causing allergy, decreasing the number of WBCs and also causing problems with blood pressure.

The study provides a decisive view on the Paclitaxel Injection market by segmenting the market based on Indication, End user and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. Based on Indication, the market is segmented into Prostate cancer, breast cancer, non-small cell lung cancer, aids related Kaposi’s sarcoma, ovarian cancer, stomach cancer, cervical cancer, esophageal cancer, testicular cancer, lung cancer, pancreatic cancer and others. According to the WHO, 723,000 deaths from stomach cancer and 521,000 deaths from breast cancer in 2012 alone. Paclitaxel is used to treat both of these cancers, and rising cancer incidences would lead to increased use of this drug for treatment. Based on the End user segment, the market is bifurcated into Cancer Research centers, Hospital and Others.

The geographical segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Due to the high incidence of cancer patients in this country, North America currently dominates the market. Nevertheless, because of rising cancer incidences, Europe and Asia Pacific are emerging markets.

The increasing incidence of cancer is the major driving force for this market's significant growth. Paclitaxel injection has better efficiency for cancer treatment than other drugs, besides that it is also readily available on the market that is responsible for this market's growth. Major players on the market for paclitaxel injection focus on developing better paclitaxel injection, which will be a remarkable opportunity for this market to grow. Many adverse effects such as blood clot, allergy, leucopenia, diarrhea, and weight loss may restrict the growth of the market for paclitaxel injection. The high cost of medication, which in low economic countries is less available, may also hamper the growth of the demand for paclitaxel injection.

Key players within global Paclitaxel Injection market include Abraxis Bio Science Inc., Celgene, Abbott Laboratories, Fresenius Kabi Oncology Ltd, Onco therapies Ltd, Novasep, Sagent Pharmaceuticals amongst others.

The report segments global Paclitaxel Injection market as follows:

Global Paclitaxel Injection Market: Indication Segment Analysis
  • Prostate cancer
  • Breast cancer
  • Non-small cell lung cancer
  • AIDS related Kaposi's sarcoma
  • Ovarian cancer
  • Stomach cancer
  • Cervical Cancer
  • Esophageal cancer
  • Testicular cancer
  • Lung cancer
  • Pancreatic cancer
  • Others
Global Paclitaxel Injection Market: End user Segment Analysis
  • Cancer Research centers
  • Hospital
  • Others
Global Paclitaxel Injection Market: Regional Segment Analysis
  • North America
  • U.S.
  • Europe
  • UK
  • France
  • Germany
  • Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • Middle East and Africa
Note: Product cover images may vary from those shown
  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Paclitaxel Injection Market, 2016-2025 (USD Million)
    • 2.2. Paclitaxel Injection Market: Snapshot
  • Chapter 3. Paclitaxel Injection Market - Industry Analysis
    • 3.1. Paclitaxel Injection Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Driver 1
      • 3.2.2. Driver 2
    • 3.3. Restraints
      • 3.3.1. Restraint 1
      • 3.3.2. Restraint 2
    • 3.4. Opportunity
      • 3.4.1. Government funding and support
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis By Indication
      • 3.6.2. Market attractiveness analysis By End user
      • 3.6.3. Market attractiveness analysis by Region
  • Chapter 4. Paclitaxel Injection Market- Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Paclitaxel Injection Market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Indication launches
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Paclitaxel Injection Market - By Indication Analysis
    • 5.1. Global Paclitaxel Injection Market overview: By Indication
      • 5.1.1. Global Paclitaxel Injection Market share, By Indication,2018 and 2025
    • 5.2. Prostate cancer
      • 5.2.1. Global Paclitaxel Injection Market by Prostate cancer, 2016-2025 (USD Million)
    • 5.3. Breast cancer
      • 5.3.1. Global Paclitaxel Injection Market by Breast cancer, 2016-2025 (USD Million)
    • 5.4. Non-small cell lung cancer
      • 5.4.1. Global Paclitaxel Injection Market by Non-small cell lung cancer, 2016-2025 (USD Million)
    • 5.5. AIDS related Kaposi's sarcoma
      • 5.5.1. Global Paclitaxel Injection Market by AIDS related Kaposi's sarcoma, 2016-2025 (USD Million)
    • 5.6. Ovarian cancer
      • 5.6.1. Global Paclitaxel Injection Market by Ovarian cancer, 2016-2025 (USD Million)
    • 5.7. Stomach cancer
      • 5.7.1. Global Paclitaxel Injection Market by Stomach cancer, 2016-2025 (USD Million)
    • 5.8. Cervical Cancer
      • 5.8.1. Global Paclitaxel Injection Market by Cervical Cancer, 2016-2025 (USD Million)
    • 5.9. Esophageal cancer
      • 5.9.1. Global Paclitaxel Injection Market by Esophageal cancer, 2016-2025 (USD Million)
    • 5.10. Testicular cancer
      • 5.10.1. Global Paclitaxel Injection Market by Testicular cancer, 2016-2025 (USD Million)
    • 5.11. Lung cancer
      • 5.11.1. Global Paclitaxel Injection Market by Lung cancer, 2016-2025 (USD Million)
    • 5.12. Pancreatic cancer
      • 5.12.1. Global Paclitaxel Injection Market by Pancreatic cancer, 2016-2025 (USD Million)
    • 5.13. Others
      • 5.13.1. Global Paclitaxel Injection Market by others, 2016-2025 (USD Million)
  • Chapter 6. Global Paclitaxel Injection Market -End user Analysis
    • 6.1. Global Paclitaxel Injection Market overview: By End user
      • 6.1.1. Global Paclitaxel Injection Market share, By End user, 2018 and 2025
    • 6.2. Cancer Research centers
      • 6.2.1. Global Paclitaxel Injection Market By Cancer Research centers, 2016-2025 (USD Million)
    • 6.3. Hospital
      • 6.3.1. Global Paclitaxel Injection Market By Hospital, 2016-2025 (USD Million)
    • 6.4. Others
      • 6.4.1. Global Paclitaxel Injection Market by Other End users, 2016-2025 (USD Million)
  • Chapter 7. Global Paclitaxel Injection Market - Regional Analysis
    • 7.1. Global Paclitaxel Injection Market overview: by Region
      • 7.1.1. Global Paclitaxel Injection Market share, by Region, 2018 and 2025
    • 7.2. North America
      • 7.2.1. North America Paclitaxel Injection Market, 2016-2025 (USD Million)
      • 7.2.2. North America Paclitaxel Injection Market revenue, By Indication,2016-2025 (USD Million)
      • 7.2.3. North America Paclitaxel Injection Market revenue, By End user, 2016-2025 (USD Million)
      • 7.2.4. The U.S.
        • 7.2.4.1. The U.S.Paclitaxel Injection Market revenue, By Indication,2016-2025 (USD Million)
        • 7.2.4.2. The U.S.Paclitaxel Injection Market revenue, By End user, 2016-2025 (USD Million)
      • 7.2.5. Rest of North America
        • 7.2.5.1. Rest of North America Paclitaxel Injection Market revenue, By Indication,2016-2025 (USD Million)
        • 7.2.5.2. Rest of North America Paclitaxel Injection Market revenue, By End user, 2016-2025 (USD Million)
    • 7.3. Europe
      • 7.3.1. Europe Paclitaxel Injection Market, 2016-2025 (USD Million)
      • 7.3.2. Europe Paclitaxel Injection Market revenue, By Indication,2016-2025 (USD Million)
      • 7.3.3. Europe Paclitaxel Injection Market revenue, By End user, 2016-2025 (USD Million)
      • 7.3.4. UK
        • 7.3.4.1. U.K.Paclitaxel Injection Market revenue, By Indication,2016-2025 (USD Million)
        • 7.3.4.2. U.K.Paclitaxel Injection Market revenue, By End user, 2016-2025 (USD Million)
      • 7.3.5. France
        • 7.3.5.1. France Paclitaxel Injection Market revenue, By Indication,2016-2025 (USD Million)
        • 7.3.5.2. France Paclitaxel Injection Market revenue, By End user, 2016-2025 (USD Million)
      • 7.3.6. Germany
        • 7.3.6.1. Germany Paclitaxel Injection Market revenue, By Indication,2016-2025 (USD Million)
        • 7.3.6.2. Germany Paclitaxel Injection Market revenue, By End user, 2016-2025 (USD Million)
      • 7.3.7. Rest of Europe
        • 7.3.7.1. Rest of EuropePaclitaxel Injection Market revenue, By Indication,2016-2025 (USD Million)
        • 7.3.7.2. Rest of EuropePaclitaxel Injection Market revenue, By End user, 2016-2025 (USD Million)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific Paclitaxel Injection Market, 2016-2025 (USD Million)
      • 7.4.2. Asia Pacific Paclitaxel Injection Market revenue, By Indication,2016-2025 (USD Million)
      • 7.4.3. Asia Pacific Paclitaxel Injection Market revenue, By End user, 2016-2025 (USD Million)
      • 7.4.4. China
        • 7.4.4.1. China Paclitaxel Injection Market revenue, By Indication,2016-2025 (USD Million)
        • 7.4.4.2. China Paclitaxel Injection Market revenue, By End user, 2016-2025 (USD Million)
      • 7.4.5. Japan
        • 7.4.5.1. Japan Paclitaxel Injection Market revenue, By Indication,2016-2025 (USD Million)
        • 7.4.5.2. Japan Paclitaxel Injection Market revenue, By End user, 2016-2025 (USD Million)
      • 7.4.6. India
        • 7.4.6.1. India Paclitaxel Injection Market revenue, By Indication,2016-2025 (USD Million)
        • 7.4.6.2. India Paclitaxel Injection Market revenue, By End user, 2016-2025 (USD Million)
      • 7.4.7. Rest of Asia Pacific
        • 7.4.7.1. Rest of Asia Pacific Paclitaxel Injection Market revenue, By Indication,2016-2025 (USD Million)
        • 7.4.7.2. Rest of Asia Pacific Paclitaxel Injection Market revenue, By End user, 2016-2025 (USD Million)
    • 7.5. Latin America
      • 7.5.1. Latin America Paclitaxel Injection Market, 2016-2025 (USD Million)
      • 7.5.2. Latin America Paclitaxel Injection Market revenue, By Indication,2016-2025 (USD Million)
      • 7.5.3. Latin America Paclitaxel Injection Market revenue, By End user, 2016-2025 (USD Million)
      • 7.5.4. Brazil
        • 7.5.4.1. Brazil Paclitaxel Injection Market revenue, By Indication,2016-2025 (USD Million)
        • 7.5.4.2. Brazil Paclitaxel Injection Market revenue, By End user, 2016-2025 (USD Million)
      • 7.5.5. Rest of Latin America
        • 7.5.5.1. Rest of Latin America Paclitaxel Injection Market revenue, By Indication,2016-2025 (USD Million)
        • 7.5.5.2. Rest of Latin America Paclitaxel Injection Market revenue, By End user, 2016-2025 (USD Million)
    • 7.6. The Middle East and Africa
      • 7.6.1. The Middle East and Africa Paclitaxel Injection Market, 2016-2025 (USD Million)
      • 7.6.2. The Middle East and Africa Paclitaxel Injection Market revenue, By Indication,2016-2025 (USD Million)
      • 7.6.3. The Middle East and Africa Paclitaxel Injection Market revenue, By End user, 2016-2025 (USD Million)
  • Chapter 8. Company Profiles
    • 8.1. Abraxis Bio Science Inc.
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Indication Portfolio
      • 8.1.4. Business Strategy
      • 8.1.5. Recent Developments
    • 8.2. Celgene
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Indication Portfolio
      • 8.2.4. Business Strategy
      • 8.2.5. Recent Developments
    • 8.3. Abbott Laboratories
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Indication Portfolio
      • 8.3.4. Business Strategy
      • 8.3.5. Recent Developments
    • 8.4. Fresenius Kabi Oncology Ltd
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Indication Portfolio
      • 8.4.4. Business Strategy
      • 8.4.5. Recent Developments
    • 8.5. Onco therapies Ltd
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Indication Portfolio
      • 8.5.4. Business Strategy
      • 8.5.5. Recent Development
    • 8.6. Novasep
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Indication Portfolio
      • 8.6.4. Business Strategy
      • 8.6.5. Recent Development
    • 8.7. Sagent Pharmaceuticals
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Indication Portfolio
      • 8.7.4. Business Strategy
      • 8.7.5. Recent Development
Note: Product cover images may vary from those shown
Adroll
adroll